CVRx to present late-breaking REBALANCE Registry real-world Barostim outcomes at HFSA 2026

By Public Technologies
  • CVRx flagged new clinical evidence for its Barostim heart-failure device ahead of the HFSA Annual Scientific Meeting in October.
  • Results have not yet been presented; late-breaking analyses from the REBALANCE real-world registry are scheduled for Oct. 11.
  • The company also highlighted first real-world evidence in HFmrEF, pointing to reduced hospitalization burden in routine commercial use.
  • Barostim data from the newly launched BENEFIT-HF trial in an expanded patient population will be shown in the meeting’s clinical trial ePoster hub.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CVRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609291630PRIMZONEFULLFEED9836047) on September 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk